MRVI has 36-month beta value of -0.07. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 6 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for MRVI is 116.80M, and currently, short sellers hold a 7.04% ratio of that float. The average trading volume of MRVI on November 18, 2024 was 2.07M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRVI) stock’s latest price update
The stock price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has dropped by -15.00 compared to previous close of 5.20. Despite this, the company has seen a fall of -12.91% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.
MRVI’s Market Performance
Maravai LifeSciences Holdings Inc (MRVI) has seen a -12.91% fall in stock performance for the week, with a -45.50% decline in the past month and a -52.16% plunge in the past quarter. The volatility ratio for the week is 12.14%, and the volatility levels for the past 30 days are at 7.65% for MRVI. The simple moving average for the past 20 days is -35.95% for MRVI’s stock, with a -45.43% simple moving average for the past 200 days.
Analysts’ Opinion of MRVI
Wells Fargo gave a rating of “Overweight” to MRVI, setting the target price at $10 in the report published on August 28th of the current year.
MRVI Trading at -43.05% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.75% of loss for the given period.
Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 12.14%, as shares sank -47.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.16% lower at present.
During the last 5 trading sessions, MRVI fell by -12.91%, which changed the moving average for the period of 200-days by -17.84% in comparison to the 20-day moving average, which settled at $6.90. In addition, Maravai LifeSciences Holdings Inc saw -32.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from DeFord John A, who purchase 17,500 shares at the price of $5.75 back on Nov 12 ’24. After this action, DeFord John A now owns 70,046 shares of Maravai LifeSciences Holdings Inc, valued at $100,625 using the latest closing price.
HULL CARL, the of Maravai LifeSciences Holdings Inc, purchase 175,000 shares at $5.64 during a trade that took place back on Nov 11 ’24, which means that HULL CARL is holding 175,000 shares at $987,000 based on the most recent closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.44 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.81. The total capital return value is set at -0.16. Equity return is now at value -51.98, with -12.67 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -7.96.
Currently, EBITDA for the company is 712.41 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 3.94. The receivables turnover for the company is 9.59for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.74.
Conclusion
To put it simply, Maravai LifeSciences Holdings Inc (MRVI) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
